Journal article
Treatment of bipolar depression
M Berk, L Berk, CG Davey, S Moylan, F Giorlando, AB Singh, H Kalra, S Dodd, GS Malhi
Medical Journal of Australia | Published : 2012
DOI: 10.5694/mjao12.10611
Abstract
Depression is usually the predominant phase in bipolar disorder, causes the most psychosocial disability, and carries significant risk of suicide.The management of bipolar depression is relatively under-studied and poses significant challenges for clinicians.There is substantial dissent regarding optimal pharmacotherapy for bipolar depression, particularly around the role of antidepressants.Individual and combination pharmacotherapy should be integrated into a personalised psychosocial and lifestyle package of interventions that considers the person’s clinical profile and preferences.The relative lack of evidence relating to optimal strategies, especially when bipolar depression occurs with ..
View full abstractGrants
Funding Acknowledgements
[ "Lesley Berk acknowledges the National Health and Medical Research Council (NHMRC) for funding her PhD scholarship.", "Michael Berk has received grant or research support from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi-Synthelabo, Servier, Solvay and Wyeth; and served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Servier. Francesco Giorlando has received grant or research support from AstraZeneca and Pfizer. Ajeet Singh has received grant or research support from Healthscope Molecular and Pfizer; and has been a speaker for AstraZeneca, Eli Lilly, Lundbeck and Pfizer. Harish Kalra has been a speaker for Eli Lilly and Pfizer. Seetal Dodd has received grant or research support from Bristol-Myers Squibb, Eli Lilly, Novartis, Mayne Pharma and Servier; and has been a speaker and served as a consultant for Eli Lilly." ]